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ABSTRACT
Introduction. The aim of this study is to compare the therapeutic results of patients with ovarian cancer 
coexisting with endometriosis with a group of patients with cancer formed in the endometriosis focus in 
the scar after caesarean section. 
Methods. We analysed the therapeutic results of patients with ovarian cancer coexisting with endometriosis 
with a group of patients with cancer formed in the endometriosis focus in the scar after caesarean section. 
They were operated in the Oncology Centre in Bydgoszcz. All the patients had endometriosis and ovarian 
cancer confirmed in one tissue preparation.
Results. The probability of death at any time is 7.826-times higher in the group with scar cancer than in 
the group with endometriosis and ovarian cancer.
Conclusions. Because scar cancer that arises in the background of endometriosis is an extremely rare 
condition and also because the prognosis for this group of patients is poor we consider it necessary to 
plan combination therapy by a multidisciplinary oncological team.
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Introduction
Uncontrolled divisions of cells, the formation of 
implants in adjacent tissue, stromal destruction, the 
ability to spread to distant organs, similar risk factors, 
and oestrogen-dependent growth — this resemblance 
between endometriosis and cancer initiated on-going 
studies that are aimed at determining the relationship 
between the two diseases [1].
Malignant transformation associated with the ecto-
pic location of endometrial tissue concerns mainly the 
ovaries (70%), and only about 25% of such cancers 
arise out of the pelvis. The proliferative process located 
in the scar after prior laparotomy is especially rare, with 
37 cases described in the literature. However, given the 
growing number of caesarean sections, it is believed 
that cancers in this location will become more frequent.
Although retrograde menstruation occurs in 70% of 
menstruating women, not all of them will develop endo-
metriosis. Therefore, the thesis has been put forward that 
individual characteristics of the immune system are re-
sponsible for the effective elimination or specific tolerance 
towards the development of endometrial tissue outside the 
uterus. Hence, this disease can be the result of ineffective 
elimination of endometrial cells from the peritoneal cavity. 
Methods
Recruitment of subjects involved a search through 
the electronic database of patients treated at the 
Oncology Centre in Bydgoszcz. The coexistence of 
endometriosis and ovarian cancer in one postoperative 
tissue specimen, confirmed in histological examina-
tion, was an inclusion criterion. Preparations, which 
were prepared in a standard manner, fixed in formalin, 
embedded in paraffin, stained with haematoxylin and 
eosin, were subject to histological reassessment, which 
confirmed endometriosis-associated ovarian carcino-
ma. Endometriosis and ovarian cancer were defined 
according to World Health Organisation guidelines. 
Fifty-three patients receiving surgical treatment at 
the Oncology Centre in Bydgoszcz were included in 
the study. 
Results
The analysis performed using the Cox model 
shows that the analysed groups differ significantly 
with regard to survival (because the p value is be-
low 0.05). HR for the group with scar tissue cancer 
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Table 1. 1-year, 3-year and 5-year survival rates and the median survival for each analysed group
Group Number  
of patients
Number 
of events 
(deaths)
Survival Median  
survival  
(months)
HR 95% CI for HR p
1-year 3-year 5-year
Endometriosis  
and ovarian 
cancer
46 13 89.13% 75.45% 75.45% > the longest  
follow-up
Ref.
Scar tissue  
cancer in 
endometriosis
7 4 51.43% 25.71% 25.71% 18.25 7.826 2.062 29.703 p = 0.003
CI — confidence interval
Figure 1. Kaplan-Meier curves: the curve for the group 
with scar tissue cancer is located lower, and it indicates 
a poorer prognosis
is 7.826, i.e. in this group the probability of death at 
any time is 7.826-times higher than in the group with 
endometriosis and ovarian cancer (Tab. 1). It can 
also be observed on Kaplan-Meier curves: a curve 
for the group with scar tissue cancer is located 
lower and it indicates a poorer prognosis (Fig. 1). 
The table can also be used to read 1-year, 3-year and 
5-year survival rates and the median survival for each 
analysed group. For example, in the group with scar 
tissue cancer 5-year survival was 25.71%, i.e. 25.71% of 
patients in this group survived for at least 5 years. In the 
group with scar tissue cancer the median survival was 
18.25 months, i.e. half of the patients in this group died 
after this time. The median survival in the group with 
endometriosis and ovarian cancer is longer than the 
duration of the longest follow-up period. It means that 
more than half of patients were alive after the end of the 
follow-up period in this group (this can be observed on 
a chart: the Kaplan-Meier curve does not reach 50%).
Discussion
Numerous studies have shown that the creation 
of endometriosis is related to the reduced activity of 
NK cells and/or macrophages [2, 3] which comprise 
macrophages, B cells, T cells, natural killer (NK). How-
ever, other works have demonstrated that the reduced 
efficiency of the immune system against autologous 
endometrial cells is not a simple relation [4, 5].
The characteristics of the tumour cell were described 
in 2011 by Hanahan and Weinberg [6]. This cell should 
have its own mechanisms of resistance against apopto-
sis, the ability to form nourishing blood vessels, invade 
neighbouring tissues, and create satellite metastatic 
lesions, as well as be insensitive to the anti-proliferative 
signals of the body and have a certain genetically con-
ditioned instability that allows for still new growth op-
portunities. Because OSE (ovarian epithelium surface) 
has pluripotent properties, e.g. the ability to undergo 
cyclic EMT (epithelial to mesenchymal transition) in the 
process of “healing” after ovulation, the hypothesis of 
frequent carcinogenesis appeared in this place [7]. 
As noted by many researchers, the presence of ovarian 
endometriosis creates a new microenvironment with 
certain disorders in the cytokine and hormonal OSE 
profile. These disorders would favour the passage of 
neoplastic transformation. Assuming that endometrio-
sis promotes the formation of the compounds with the 
properties of growth factors for cancer cells and causes 
the existence of a chronic inflammatory effect, over time 
it increases the chance of accumulation of mutations 
during the process of DNA transcription and repair. 
Balkwill and Mantovani emphasise the role of chronic in-
flammation in the course of carcinogenesis by Virchow, 
who as early as in the nineteenth century observed 
that chronic inflammation promoted the formation of 
certain types of cancers [8]. Uncontrolled, excessive 
cell proliferation causes the response from the tumour 
cell microenvironment by producing chemotactic 
substances aimed at mobilising macrophages and 
monocytes [9]. Alluvial macrophages releasing growth 
factors (VEGF-A, VEGF-C, TNF, HGF, EGF, PDGF), and 
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chemokines (CXCL12 and IL-8) exacerbate inflamma-
tion [10]. It is emphasised that the role of macrophages 
infiltrating the tumour is not clear. It has been observed 
that stimulation of the tumour development in certain cir-
cumstances may be responsible for its destruction [11]. 
Most studies indicate, however, that growth and 
pro-inflammatory factors, which are produced by mac-
rophages, promote welfare of the tumour to a greater 
degree than induction of the effective antitumor immune 
response [8]. It has been demonstrated that they play 
an important role in the formation of satellite changes 
and induction of the metastatic stage of tumour. Having 
proteolytic activity, they initiate the stage of microinva-
sion of stroma by tumour cells through degradation of 
the basement membrane [12]. In their work, Mantovani 
et al. [13] showed that the activation of tumour-asso-
ciated macrophages (TAMs) is an essential step in the 
initiation of metastasis.
Causing abnormal cytokine and hormonal milieu 
ovarian endometriosis approaches toward the expres-
sion profile, which is typical of cancer of this organ. Per-
sistent and over again exacerbated inflammation, which 
is caused by the presence of ectopic endometrial cells, 
produces the specific microenvironment with many cells 
and even more intracellular signals. Clonal proliferation 
of endometrial cells in the development of ectopic en-
dometrial tissue has to create the microenvironment 
conditioning and supporting this change. The microen-
vironment with at least part of an ovarian tissue will be 
influenced by the same factors that guarantee clonal, 
ectopic, and autonomous growth. The multiplicity of 
divisions, accompanying DNA repairs and chronic 
inflammation, which is always connected with ectopic 
endometrial changes, facilitates the accumulation of 
mutations as an unrecoverable error inevitably leading 
to malignant transformation. The induction of persistent 
inflammation, which is a characteristic of endometriosis, 
has local and distant systemic consequences [14]. 
Increased expression of proinflammatory chemokines 
IL-1, IL-6, IL-8 and TNF-a in the course of ongoing 
inflammation has a major impact on the stability of the 
endometrial tissue in ectopic locations [15].
Chronically-stimulated immune effector cells reg-
ulate intracellular signal transduction cascades by 
the transcription factor NFkB, which is a certain link 
between carcinogenesis and inflammation [16]. On the 
other hand, chronically activated immune cells inhibit 
the anti-tumour response acquired by the immune sys-
tem continuously during smouldering of inflammation. 
NFkB controls many processes necessary for cancer 
to achieve autonomy, such as resistance to apoptosis, 
neoangiogenesis, independence in growth signals, 
stromal invasion, and formation of metastases [6]. The 
direct participation of NFkB in the formation of metasta-
ses was described by Luo et al. [17]. A decrease in the 
expression of the nuclear factor resulted in the reduction 
of tumour growth driven by inflammation. Furthermore, 
it has been shown that this factor is activated not only 
by the stimulant effect from the microenvironment, but 
also by the genetic background [18].
Conclusions
Due to the extremely poor prognosis for patients 
with scar cancer coexisting with endometriosis we 
consider it necessary for a multidisciplinary oncological 
team to plan combination therapy. We do believe that 
radiotherapy is an essential part of adjuvant treatment.
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